A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/19/2002	WO2002100877A1 Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
12/19/2002	WO2002100851A2 Thiophene derivatives as antiviral agents for flavivirus infection
12/19/2002	WO2002100846A1 Compounds and methods for the treatment or prevention of flavivirus infections
12/19/2002	WO2002100845A1 Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	WO2002100844A2 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	WO2002100836A2 Compounds, compositions and methods for modulating beta-amyloid production
12/19/2002	WO2002100827A2 Method for increasing the survival of dopamine secreting cells
12/19/2002	WO2002100825A2 Anthranilic acid amides with a heteroarylsulfonyl side chain, and use thereof as antiarrhythmic active substances
12/19/2002	WO2002100813A2 Modulators of peroxisome proliferator activated receptors
12/19/2002	WO2002100441A2 Method for treatment of vascular regeneration
12/19/2002	WO2002100434A1 Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists
12/19/2002	WO2002100429A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002	WO2002100428A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002	WO2002100421A1 Low molecular weight components of cartilage, complexes of copper with amino acids or di-peptides; processes for preparation and therapeutic uses thereof
12/19/2002	WO2002100415A2 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
12/19/2002	WO2002100410A1 Methods of treating alzheimer's disease
12/19/2002	WO2002100408A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
12/19/2002	WO2002100403A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	WO2002100392A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
12/19/2002	WO2002100391A1 Swallow tablet comprising paracetamol
12/19/2002	WO2002100390A2 Improved method of treating the syndrome of coronary heart disease risk factors in humans
12/19/2002	WO2002100386A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002	WO2002100383A1 Porous sponge-like cellulosic material for treatment of injuries
12/19/2002	WO2002100359A1 Preparation for hair and/or scalp
12/19/2002	WO2002100355A1 A prepreg, a composite and their uses
12/19/2002	WO2002100353A2 Cd10-activated prodrug compounds
12/19/2002	WO2002100352A2 Nr2b receptor antagonists for the treatment or prevention of migraines
12/19/2002	WO2002100351A2 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002	WO2002100348A2 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	WO2002100347A2 Prodrugs of gaba analogs, compositions and uses thereof
12/19/2002	WO2002100336A2 Tissue-specific endothelial membrane proteins
12/19/2002	WO2002100329A2 Methods and compositions for helping the body resist the effects of the aging process
12/19/2002	WO2002100328A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	WO2002100193A1 Body temperature-raising agent of amino acids for eating or drinking and for medical use
12/19/2002	WO2002100148A2 Treatment or prophylaxis of insulin-producing cell graft rejection
12/19/2002	WO2002087583A3 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
12/19/2002	WO2002085327A3 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
12/19/2002	WO2002085308A3 Antisense and anti-inflammatory based compositions to treat respiratory disorders
12/19/2002	WO2002082075A9 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
12/19/2002	WO2002080981A3 Polynucleotide binding complexes comprising sterols and saponins
12/19/2002	WO2002078684A3 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
12/19/2002	WO2002076388A3 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
12/19/2002	WO2002072544A3 Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070515A3 Chromane derivatives, process for their preparation and their use as antitumor agents
12/19/2002	WO2002067864A3 Coenzyme q products exhibiting high dissolution qualities
12/19/2002	WO2002066624A3 Novel human protease and polynucleotides encoding the same
12/19/2002	WO2002065981A3 Chemotherapeutic composition using calcium phosphate paste
12/19/2002	WO2002064087A3 Neurotherapeutic use of carboxypeptidase inhibitors
12/19/2002	WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002	WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002	WO2002058705A3 Degradation-resistant glucocorticosteroid formulations
12/19/2002	WO2002058681A3 Use of rhein for preparing a medicine for treating a high level of il-1
12/19/2002	WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders
12/19/2002	WO2002056878A3 Pharmaceutical composition having reduced tendency for drug crystallization
12/19/2002	WO2002055085A3 Use of an adenosine a3 receptor agonist for inhibition of viral replication
12/19/2002	WO2002042248A3 Naphthalene derivatives
12/19/2002	WO2002012338A3 Screening method
12/19/2002	WO2002011767A3 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l
12/19/2002	WO2002005836A3 Stimulation of bone growth with thrombin peptide derivatives
12/19/2002	WO2002005795A3 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
12/19/2002	WO2001087301A9 Methods for treatment of inflammatory diseases
12/19/2002	WO2001077169A9 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
12/19/2002	WO2001072977A9 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
12/19/2002	WO2001068679A9 Peptides targeting specifically tumor-derived endothelial cells
12/19/2002	WO2001041748A3 Pharmaceutical combinations and their use in treating gastrointestinal disorders
12/19/2002	US20020194633 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
12/19/2002	US20020193875 Agent promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin
12/19/2002	US20020193849 Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
12/19/2002	US20020193729 Microprojection array immunization patch and method
12/19/2002	US20020193610 Indazoles
12/19/2002	US20020193429 Methods for treating neuropsychiatric disorders
12/19/2002	US20020193420 Neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compounds are nonimmunosuppressive, has an affinity for FKBP type immunophilins
12/19/2002	US20020193416 Synergistic tumorcidal response induced by histamine
12/19/2002	US20020193415 Phenylindoles for the treatment of HIV
12/19/2002	US20020193403 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
12/19/2002	US20020193397 Nasal delivery of apomorphine
12/19/2002	US20020193373 Therapy of disorders of the outer retina by administering a pharmaceutically effective amount of a beta -adrenoceptor antagonist
12/19/2002	US20020193370 For therapy and prophylaxis of ophthalmic, otic or nasal infections and attendant inflammation
12/19/2002	US20020193369 Antifungal compounds and uses therefor
12/19/2002	US20020193360 For enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease
12/19/2002	US20020193344 Acid controlled induced viscosity fiber system and uses thereof
12/19/2002	US20020193340 Method of treating dry eye disease with purinergic receptor agonists
12/19/2002	US20020193339 Antiviral agent for use in treatment of cancer
12/19/2002	US20020193333 For immunization for the therapy of diseases with or without combination chemotherapy
12/19/2002	US20020193326 Methods of inhibiting proliferative diseases
12/19/2002	US20020193321 Shelf life
12/19/2002	US20020193318 Administering compound that binds human serum albumin (HSA) to increase free drug levels of the camptothecin compound during anti-topoisomerase I-based therapy in human
12/19/2002	US20020193313 Alternately providing to tumor first second nutritional solutions while depriving tumor of other external sources of nutrition; determining when tumor cells that are synchronously in S phase of the cell cycle is elevated; chemotherapy
12/19/2002	US20020193309 Contacting the sample or tissue with fibroblast growth factor 9 (FGF9) and allowing formation of receptor-ligand pairs; detecting presence of FGFR3-FGF9 pairs, a positive detection indicating presence of FGFR3 in the sample or tissue
12/19/2002	US20020193307 Antagonism of endothelin actions
12/19/2002	US20020193306 Treatment of allergic rhinitis
12/19/2002	US20020193304 Anti-HIV agents
12/19/2002	US20020193291 Treating NIDDM with RXR agonists
12/19/2002	US20020193288 Methods of treating hypertension and compositions for use therein
12/19/2002	US20020192822 Herpes simplex virus ICP4 is an inhibitor of apoptosis
12/19/2002	US20020192785 For use in therapeutics, diagnostics, and as research tools
12/19/2002	US20020192737 Detecting modulators of oxidoreductases; obtain sample, incubate with modulator, detect signal, monitor adjustment in enzyme activity

1 ... 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 ... 1151